Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Functional Abnormalities in Experimental Pyelonephritis

      , , ,

      Nephron

      S. Karger AG

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          (1) Concentrating ability was studied in rats with experimental pyelonephritis. Maximal urinary concentration was shown to be reduced as early as one week after introduction of infection and persisted unchanged up to 21 weeks with repetitive injections of bacteria. (2) Glomerular filtration rate was unaltered throughout the study period. PAH clearance fell in the repetitively injected animals. (3) Sodium content of the renal papilla remained normal but urea content fell in the one-week singly injected and 21-week repetitively injected animals. (4) Histological examination showed progressive dilatation of residual collecting ducts. (5) It is suggested that the concentrating defect in early experimental pyelonephritis is due to impaired permeability of the collecting ducts to urea and water.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1965
          1965
          25 November 2008
          : 2
          : 4
          : 193-206
          Affiliations
          Medical Service, Wadsworth Hospital, Veterans Administration Center and the Department of Medicine, UCLA Center for the Health Sciences, Los Angeles, Calif.
          Article
          179403 Nephron 1965;2:193–206
          10.1159/000179403
          4955434
          © 1965 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 14
          Categories
          Paper

          Cardiovascular Medicine, Nephrology

          Comments

          Comment on this article